Summary We determined factors associated with serum sclerostin in 446 Afro-Caribbean family members. Age, weight, sex, diabetes and kidney function were associated with sclerostin. Sclerostin was heritable, and nine SNPs in the SOST gene region were associated with sclerostin. Variation in serum sclerostin is a heritable factor that is determined by both genetic and environmental factors. Introduction Sclerostin, encoded by the SOST gene, is a Wnt inhibitor that regulates bone mineralization and is a candidate gene locus for osteoporosis. However, little is known about the genetic and non-genetic sources of inter-individual variation in serum sclerostin levels. Methods Serum sclerostin was measured in 446 AfroCaribbean men and women aged 18+ from seven large, multigenerational families (mean family size, 64; 3,840 relative pairs). Thirty-six common single nucleotide polymorphisms (SNP) were genotyped within a 100 kb region encompassing the gene encoding sclerostin (SOST). Genetic and non-genetic factors were tested for association with serum sclerostin. Results Mean serum sclerostin was 41.3 pmol/l and was greater in men than in women (P <0.05). Factors associated with higher serum sclerostin were increased age and body weight, male sex, diabetes and decreased glomerular filtration rate, which collectively accounted for 25.4 % of its variation. Residual genetic heritability of serum sclerostin was 0.393 (P <0.0001). Nine SNPs reached nominal significance with sclerostin. Three of those nine SNPs represented independent association signals (rs851056, rs41455049 and rs9909172), which accounted for 7.8 % of the phenotypic variation in sclerostin, although none of these SNPs surpassed a Bonferroni correction for multiple comparisons. Conclusions Serum sclerostin is a heritable trait that is also determined by environmental factors including age, sex, adiposity, diabetes and kidney function. Three independent common SNPs within the SOST region may collectively account for a significant proportion of the variation in serum sclerostin.
Introduction
Sclerostin, encoded by the SOST gene, is a secreted glycoprotein that regulates skeletal mineralization by inhibiting Wnt signaling [1] [2] [3] . Although widely thought to be an osteocyte-specific protein [4] , there is evidence that the SOST mRNA is expressed by other cells including articular chondrocytes, cementocytes [5, 6] , and cells of the liver, blood vessels and kidneys [7] . However, the major source of circulating sclerostin and its potential functions outside of the skeleton are less well known.
In humans, the absence of sclerostin due to autosomal recessive mutations in SOST causes sclerosteosis [7] [8] [9] [10] and van Buchem disease [11, 12] , skeletal disorders associated with overgrowth and hypermineralization. Genetic association studies have also implicated SOST as a locus for normal variation in bone mineral density (BMD) in the general population [13] [14] [15] [16] [17] [18] [19] [20] . Currently, there is much interest in sclerostin as a potential therapeutic target in osteoporosis [21] . Preliminary data from phase 2 clinical trials of anti-sclerostin antibodies in osteoporotic patients have shown gains in BMD that significantly exceeded those with oral alendronate or subcutaneous teriparatide (McClung et. al., ASBMR 2012) . However, much remains to be learned about circulating sclerostin, including its sources of biological variability and potential genetic determination. A more thorough understanding of the genetic determination of sclerostin may ultimately aid in the development of novel personalized approaches in the care of patients with bone mineral disorders. Thus, in the current study, we investigated the heritability, environmental correlates and genetics of serum sclerostin concentrations in large, multigenerational families of African ancestry, who have high bone mineral density [22] .
Materials and methods

Tobago family health study
Briefly, probands were recruited without regard to medical history from a population-based cohort study of body composition on the Caribbean island of Tobago [23] . Probands were eligible if they had a spouse willing to participate and had at least six living offspring and/or siblings aged ≥18 years residing in Tobago. All first-, second-, and third-degree relatives of the probands were invited to participate. While eight probands were initially used for recruitment, two families were subsequently linked. The final sample consisted of 471 individuals belonging to seven independent, large and multigenerational families. The serum sclerostin levels were measured in 446 individuals who form the basis of the current analyses (mean family size, 64; 3,840 relative pairs). The Tobago Division of Health and Social Services and the University of Pittsburgh Institutional Review Boards approved the study. Written informed consent was obtained from each participant.
Serum sclerostin and other biochemical assays
Blood samples were collected from participants in the morning after an overnight fast. The serum was separated and stored at −80°C until time of assay. The serum sclerostin levels were measured according to the manufacturer's protocol using a validated sandwich ELISA assay (Biomedica Gruppe, Vienna, Austria). Intra-and inter-assay coefficients of variation are 5 and 3 %, respectively. Fasting serum glucose was measured using a coupled enzymatic reaction similar to the procedure described by Bondar and Mead [24] . Insulin was measured according to the manufacturer's protocol using an RIA procedure (Linco Research, Inc., St. Charles, MO, USA). The degree of insulin resistance was estimated by the homeostasis model of assessment-insulin resistance (HOMA-IR) which was calculated as fasting serum glucose (mmol/l)×fasting serum insulin (μU/ml)) / 22.5 [25] . The kidney function was assessed using the estimated glomerular filtration rate (eGFR) as modeled by the Modification of Diet in Renal Disease equation [26] using serum creatinine levels that were measured by the VITROS CREA slide method according to standard protocols.
Other characteristics
Body weight was measured to the nearest 0.1 kg on a balance beam scale, and standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer, both without participants wearing shoes. The BMI was calculated as weight in kilograms divided by standing height in square meters. The total body percent fat was assessed by dual energy X-ray absorptiometry (DXA) using a Hologic QDR-4500 W densitometer (Hologic Inc., Bedford, MA, USA). Standardized procedures for participant positioning and scan analysis were followed according to the manufacturer's recommended protocol. The scans were analyzed with QDR software version 8.26a. The short-term in vivo precision of the DXA measurement was assessed with repositioning in 12 subjects. The coefficient of variation was 0.96 % for total fat. A phantom was scanned daily and reviewed to maintain longitudinal quality assurance of the scanner during the course of the study.
Demographic, lifestyle and medical history information were collected by trained clinic staff through the administration of a questionnaire by interview. Race was based on self-report of grandparental ethnic origin. The Tobago population is predominately of West African origin with <6 % admixture [27] . Physical activity was assessed by the number of minutes walked per week, and the participants were dichotomized into "not active" or "active", determined by a median split (≤25 min vs. >25 min walked/week, respectively). Smoking status was classified as either current or not, and the participants reporting smoking <100 cigarettes in their lifetime were considered nonsmokers. Alcohol consumption was coded as having more than or equal to two drinks per week (yes/no) as there was a very low prevalence of substantial alcohol intake. Women were considered post-menopausal only if they had no menses for at least 12 months and were >40 years old, or if they had a hysterectomy or bilateral ovariectomy.
Diabetes was defined as a fasting serum glucose level ≥126 mg/dl or current use of diabetes medication [28] . Blood pressure was measured three times throughout the clinical exam, and the measures used in this analysis were the average of the second and third reading. Hypertension was defined as a seated SBP of ≥140 mmHg, DBP of ≥90 mmHg and/or current use of antihypertensive medication [29] . For analyses including continuous measures of glucose, insulin, HOMA-IR, SBP or DBP, we excluded individuals on medication for diabetes (N = 24, 5.4 %) or hypertension (N =39, 8.7 %), as appropriate.
Genotyping
We used a single nucleotide polymorphism (SNP) tagging procedure to genotype common variation 50 kb up-and downstream of the SOST gene transcription site. We identified all common variations in this region with ≥5 % minor allele frequency (MAF) in Yoruban samples using the International HapMap database (Release 27, Phase II+III found at http:// hapmap.ncbi.nlm.nih.gov/). Then, using the program HaploView [30] , we selected a subset of SNPs that predicted the remainder of the SNPs in this region with r 2 ≥0.80. There were 33 SNPs that tagged the 46 common SNPs in the SOST region with a mean r 2 of 0.98. In addition, we genotyped six SNPs from the literature which were associated with BMD [20, 31] , for a total of 39 attempted SNPs.
Genomic DNA was isolated from the whole blood extracted by the salting out method or by Qiagen column procedure (Qiagen, Santa Clara, CA, USA). The genotyping was completed by iPlex mass spectroscopy (Sequenom Inc., San Diego, CA, USA) or TaqMan (Applied Biosystems Inc., Carlsbad, CA, USA). We excluded SNPs that failed to meet the HardyWeinberg equilibrium (HWE) at a P value <0.0001 (Supplemental Table) . Out of the 39 attempted SNPs, 2 were unable to be genotyped by iPlex (1 tag and 1 previously reported [20] ) and 1 failed quality control screening due to violation of HWE and <70 % genotyping rate. The average genotyping completeness rate was 98 %, and the average genotyping consensus rate among the 5 % blind replicate samples was 99 %. The resulting 36 genotyped SNPs captured 93 % of the common variation in the 105.1-kb region spanning the SOST gene with a mean r 2 =0.98. The 36 genotyped SNPs were in linkage disequilibrium (r 2 >0.8) with 158 out of the 288 SNPs with a minor allele frequency ≥5 % in this region within the more comprehensive 1000 Genomes variant data [32] (Supplemental Figure) .
Statistical analysis
All traits were assessed for non-normality and transformed as necessary. Outliers, defined as ≥4 SD from the mean, were removed for each trait; no more than two observations were removed from any trait. To determine significant correlates of serum sclerostin concentrations, we first tested each potential covariate separately in an age-and sex-adjusted model using the variance component framework implemented in the Sequential Oligogenic Linkage Analysis Routines (SOLAR) program [33] . All potentially significant covariates (P <0.10) were then assessed simultaneously. The variables with high colinearity (e.g., body weight and BMI) were assessed in separate models, and the model with the greatest percent covariance explained and lowest P value was chosen. We required a P value of <0.05 for inclusion in the final model.
Maximum likelihood methods were used to simultaneously model the effect of additive genetics, or heritability (h 2 ), fixed covariate effects and error for serum sclerostin [33, 34] . Heritability reported herein is the residual heritability (h r 2 ), which is estimated as the proportion of phenotypic variation after the effects of the covariates are removed. We used SOLAR to estimate the residual heritability and the variance attributable to the fixed covariate effects of sclerostin. To compare the effects of the covariates, we calculated the absolute difference (calculated as beta coefficient×unit) in sclerostin per unit increase in covariate. For continuous variables, the unit range was 1 SD except for age, which was presented per 10-year difference. For dichotomous variables, the unit range was 1.
All common SNPs were tested for Mendelian inconsistencies, and any inconsistent genotypes were excluded. No more than three genotypes were removed for any SNP. Genetic association analyses of the common variants with sclerostin levels were tested, assuming additive, dominant and recessive inheritance models. For the additive model, a variable was constructed to test if none, one or two minor alleles were associated with sclerostin by regressing the sclerostin levels on the allele count. For the dominant inheritance model, a variable was constructed to combine the individuals with one or two copies of the minor allele and tested for differences in mean sclerostin level versus the group without any minor alleles. For the recessive inheritance model, a variable was constructed to combine individuals with none or one copy of the minor allele and tested for differences in mean sclerostin level versus the group with two copies of the minor allele. Due to sample size constraints, for any SNP in which there were less than or equal to five individuals with two copies of the minor allele, the SNP was tested only using the dominant model. All the genetic association tests were adjusted for the full covariate model. To determine significant, statistically independent SNPs, we added all the significant SNPs into one full covariate model and used both forward and backward selections to determine the set of SNPs that explained the greatest variance in serum sclerostin. Statistical analysis was performed using SOLAR to account for the complex structure of our families.
Results
Population characteristics
The participants were aged 43 years on average (range 18-90), and 61.2 % were female ( Table 1 ). The mean age did not differ between sexes. The participants were overweight on average (mean BMI=28.2 kg/m 2 ), and women had significantly greater BMI and total body fat than men. Diabetes prevalence was 9.4 %, and while diabetes prevalence was similar between sexes, women had significantly greater fasting serum insulin and HOMA-IR than men. Hypertension prevalence was 28.3 % and was similar between the sexes. The kidney function as assessed by eGFR was similar between sexes. Men were more likely to walk ≥25 min/week than women. While the prevalence of current smoking and moderate alcohol intake were low, men were significantly more likely to be current smokers and have more than or equal to two alcoholic drinks per week than women.
Serum sclerostin levels
The mean serum sclerostin concentration was 41.3 pmol/l, with men having about 0.25 SD higher sclerostin than women (P value <0.05, Table 1 ). All the variables from Table 1 were tested for potential association with sclerostin, after inclusion of age and sex ( Table 2 ). The correlates of serum sclerostin (P value <0.10) included age, female sex, body weight, BMI, total body fat, standing height, diabetes, glucose, HOMA-IR, DBP, eGFR, walking ≥25 min/week and being a non-smoker.
Only age, sex, body weight, diabetes and eGFR remained in the multivariable model (Table 2) . Body mass index, total body fat and serum glucose were also statistically significant correlates of serum sclerostin in the final multivariable models when substituted for the highly correlated traits-body weight or diabetes. However, body weight and diabetes explained more of the variance in sclerostin than did BMI, total body fat or serum glucose and, therefore, were included in the final model. After adjustment for all factors, for every 10-year greater age, sclerostin was 3.1 pmol/l greater (P value <0.0001). Female sex was associated with 5.2-pmol/l lower sclerostin (P value= 0.0047). Every 18.3-kg greater body weight was associated with 2.6-pmol/l greater sclerostin (P value = 0.0041). Diabetics had 10.8-pmol/l greater sclerostin than nondiabetics (P value=0.0008). Every 27.4-ml/min/1.73 m 2 greater eGFR was associated with a 3.3-pmol/l lower sclerostin (P value=0.0097). These four factors explained 25.4 % of the total variance in serum sclerostin in these African ancestry families.
Our family-based study design enabled us to estimate the genetic contribution to serum sclerostin levels. The residual heritability (h r 2 ) was 0.412 after adjustment for age and sex (P value <0.0001). After additional adjustment for all significant covariates, the residual heritability remained significant at 0.393 (P value <0.0001).
Genetic association analysis of common SOST variation
After adjustment for age, sex, body weight, diabetes and eGFR, 9 of the 36 SNPs reached nominal significance with sclerostin levels (P <0.05, Table 3 ). Each SNP individually explained 0.8-3.4 % of the phenotypic variation in the serum sclerostin levels. The strongest associations were with rs851056, rs41455049 and rs9783823 (all P values <0.01). Furthermore, an additional multivariable model showed that three SNPs (rs851056, rs41455049 and rs9909172) represented statistically independent associations with serum sclerostin and collectively accounted for 7.8 % of its phenotypic variance (data not shown). However, none of these SNPs surpassed the significance threshold when using the conservative Bonferroni multiple comparisons adjustment. 
Discussion
To our knowledge, this is the first report to comprehensively examine both the non-genetic and genetic determinants of the Wnt antagonist sclerostin. To address this aim, we measured serum sclerostin and genotyped 36 single nucleotide variants across a 100 kb region encompassing the SOST gene in 446 African ancestry individuals from seven large, multigenerational families. We found that serum sclerostin was significantly higher in males and diabetics, and increased with age, adiposity and poorer kidney function. However, these factors only explained 25 % of the inter-individual variation in serum sclerostin. We also found a significant genetic contribution to serum sclerostin in these African ancestry families. Further, we identified nine common single nucleotide variants that accounted for 7.8 % of the phenotypic variance in serum sclerostin, independent of each other and the non-genetic factors.
There have been few reports on the distribution of circulating sclerostin in healthy individuals [35] [36] [37] [38] [39] , and no reports in the African ancestry individuals, to our knowledge. The mean circulating sclerostin was 41.3 pmol/l and appears to be comparable to sclerostin levels in healthy, white individuals of similar age [36] [37] [38] . The serum sclerostin in the women from our study is about 10 pmol/l greater than the levels in a study of pre-and post-menopausal Middle Eastern women [39] . Additionally, in our study, the serum sclerostin increased with age and was about 5 pmol/l greater in men than in women, which was similar to previous reports [35] [36] [37] [38] . These data suggest that there may be important sex but unknown ethnic differences in circulating sclerostin levels that should be tested directly in future studies.
We found that serum sclerostin was also independently associated with diabetes, adiposity and kidney function. Others have also shown that serum sclerostin is greater in diabetics than those in controls [37, 40] . Among the 74 type 2 diabetics and 50 age-matched Caucasian controls, diabetics had 12.4 pmol/l greater sclerostin than non-diabetics [37] . We found very similar results in our families, with sclerostin being 12.0 pmol/l greater in untreated diabetics than that in nondiabetics. Wnt signaling is known to influence the pancreatic islet cell function and glucose metabolism [41] . However, it is currently unclear if sclerostin influences diabetes directly or if diabetes influences sclerostin levels.
Our results also agree with previous reports in Caucasians [36] and Asians [42] , which found that increased serum sclerostin levels are associated with increased body weight and BMI. Body weight, BMI and percent body fat were each significantly associated with sclerostin in our study. However, there was also a previous report that showed greater serum sclerostin to be associated with weight loss in older adults [43] . While the Wnt signaling is known to inhibit adipogenesis [44] , the role of sclerostin in the regulation of adipogenesis and body weight is currently unclear. Lastly, we found that increased sclerostin was associated with decreased kidney function as estimated by eGFR. While a previous study on chronic kidney disease (CKD) patients reported a significant association between sclerostin and eGFR [38] , this is the first study to report a significant association in healthy individuals. As SOST is highly expressed in the kidneys [6] , it may play a role in the regulation of bone metabolism by the kidneys, as previously suggested [45] .
While lifestyle factors such as physical activity and smoking were not statistically significant after full adjustment in the multivariable model, their association with serum sclerostin in the age-and sex-adjusted model may suggest that these factors influence serum sclerostin metabolism. Additionally, it is likely that the variation in the number and/or function of osteocytes and other cell types that express SOST play an important role in sclerostin regulation. In the future, it will be important to design additional studies with the explicit aim of understanding the impact of individual biology and additional lifestyle factors on serum sclerostin levels.
In addition to characterizing the epidemiologic correlates of sclerostin, we sought to identify potential genetic influences on circulating sclerostin levels. We found that sclerostin is significantly heritable in our African ancestry families (h r 2 0.393, P value <0.0001). To investigate the potential association of common genetic variation with serum sclerostin, we also genotyped SNPs within a 50-kb region up-and downstream of the SOST gene using a tagging SNP approach. We found significant associations for nine SNPs which individually explained 0.8-3.4 % of the variation in serum sclerostin levels. A subset of three SNPs (rs851056, rs41455049 and rs9909172) was independently associated with serum sclerostin and accounted for nearly 8 % of its phenotypic variance. However, given our relatively small sample size, none of these SNPs passed a conservative Bonferroni adjustment for multiple comparisons. While there was some residual linkage disequilibrium between these SNPs (Supplemental Figure) , they were statistically independently associated with sclerostin, suggesting that they may represent at least three independent genetic signals. The statistical model containing all the significant covariates and these three SNPs explained 33 % of the total phenotypic variance in serum sclerostin levels in our families.
One of the most widely replicated SNPs in SOST, rs851056, which is associated with BMD [13] [14] [15] , also explained the greatest variation in serum sclerostin levels in our study. This SNP resides about 1 kb upstream of the transcription start site of SOST and is 500 bases away from rs851054, another variant that was strongly associated with serum sclerostin in our study. These SNPs lie within or near the potential transcription factor motifs for AP-2 (rs851054) and c-Myc (rs851056). Additionally, these SNPs have been associated with areal spine BMD in Spanish post-menopausal women [14] , volumetric spine BMD in older Caucasian men [15] and total hip BMD in Australian post-menopausal women [13] . However, the SNP most significantly associated with serum sclerostin in our study (rs41455049) is located about 26 kb upstream of SOST. This SNP is located within a potential JunD transcription factor binding motif and an area of histone modification in osteoblasts, which may be involved in the regulation of SOST.
Previous studies have also identified a 50-kb deletion located 32 kb downstream of SOST that is responsible for van Buchem disease [11, 12] . Genetic association studies in Caucasian and Asians [15, 16, 19, 20] have identified the SNPs in or near this region to be associated with BMD. We genotyped six SNPs within this 50-kb region, which were associated with BMD in previous studies, along with three additional tagging SNPs (Supplemental Table) . One SNP representing an independent genetic signal for serum sclerostin levels (rs9909172, Table 3 ) resides within this region. Individuals with two copies of the minor allele of rs9909172 had~8-pmol/l lower sclerostin levels. This SNP was previously associated with osteoporotic fracture in a meta-analysis [20] . While our study was initiated prior to the availability of 1,000 Genomes data [32] , a post hoc analysis revealed that our 36 SNPs covered 54 % of the common variation found across the SOST region in this comprehensive database. It is likely that other genetic signals may exist within this region, but additional larger studies will be needed to comprehensively evaluate all common and rare genetic variations in this and other populations.
In conclusion, we investigated the potential sources of interindividual variability in serum sclerostin in African ancestry individuals and their association with common genetic variation in the SOST gene region. We found that serum sclerostin is a heritable trait that is independently associated with age, sex, adiposity, diabetic status and eGFR. Our genotyping analysis also revealed that individual common variants in the SOST gene region each accounted for up to 3.4 % of the variance in sclerostin, with three independent genetic signals collectively accounting for 8 % of the variance. A better understanding of the genetic basis of serum sclerostin may ultimately aid in the development of individualized approaches to treating patients with bone mineral disorders.
